|
1
|
Mirza F and Canalis E: Management of
endocrine disease: Secondary osteoporosis: Pathophysiology and
management. Eur J Endocrinol. 173:R131–R151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sheu A and Diamond T: Secondary
osteoporosis. Aust Prescr. 39:85–87. 2016.PubMed/NCBI
|
|
3
|
Colangelo L, Biamonte F, Pepe J, Cipriani
C and Minisola S: Understanding and managing secondary
osteoporosis. Expert Rev Endocrinol Metab. 14:111–122. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rooney M, Bishop N, Davidson J, Beresford
MW, Pilkington C, Donagh JM, Wyatt S, Gardner-Medwin J, Satyapal R,
Clinch J, et al: The prevention and treatment of
glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A
randomised double-blind controlled trial. EClinicalMedicine.
12:79–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caplan L and Saag KG: Glucocorticoids and
the risk of osteoporosis. Expert Opin Drug Saf. 8:33–47. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buckley L, Guyatt G, Fink HA, Cannon M,
Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, et
al: 2017 American college of rheumatology guideline for the
prevention and treatment of glucocorticoid-induced osteoporosis.
Arthritis Rheumatol. 69:1521–1537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McGee-Lawrence ME and Westendorf JJ:
Histone deacetylases in skeletal development and bone mass
maintenance. Gene. 474:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Westendorf JJ: Histone deacetylases in
control of skeletogenesis. J Cell Biochem. 102:332–340. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jensen ED, Schroeder TM, Bailey J,
Gopalakrishnan R and Westendorf JJ: Histone deacetylase 7
associates with Runx2 and represses its activity during osteoblast
maturation in a deacetylation-independent manner. J Bone Miner Res.
23:361–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee HW, Suh JH, Kim AY, Lee YS, Park SY
and Kim JB: Histone deacetylase 1-mediated histone modification
regulates osteoblast differentiation. Mol Endocrinol. 20:2432–2443.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schroeder TM and Westendorf JJ: Histone
deacetylase inhibitors promote osteoblast maturation. J Bone Miner
Res. 20:2254–2263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Kwon S, Yamaguchi T, Cubizolles
F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, et al:
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but
are viable and develop normally. Mol Cell Biol. 28:1688–1701. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dudakovic A, Evans JM, Li Y, Middha S,
McGee-Lawrence ME, van Wijnen AJ and Westendorf JJ: Histone
deacetylase inhibition promotes osteoblast maturation by altering
the histone H4 epigenome and reduces Akt phosphorylation. J Biol
Chem. 288:28783–28791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eslaminejad MB, Fani N and Shahhoseini M:
Epigenetic regulation of osteogenic and chondrogenic
differentiation of mesenchymal stem cells in culture. Cell J.
15:1–10. 2013.PubMed/NCBI
|
|
15
|
Kretsovali A, Hadjimichael C and
Charmpilas N: Histone deacetylase inhibitors in cell pluripotency,
differentiation, and reprogramming. Stem Cells Int.
2012:1841542012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Menegola E, Di Renzo F, Broccia ML and
Giavini E: Inhibition of histone deacetylase as a new mechanism of
teratogenesis. Birth Defects Res C Embryo Today. 78:345–353. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rimando MG, Wu HH, Liu YA, Lee CW, Kuo SW,
Lo YP, Tseng KF, Liu YS and Lee OK: Glucocorticoid receptor and
Histone deacetylase 6 mediate the differential effect of
dexamethasone during osteogenesis of mesenchymal stromal cells
(MSCs). Sci Rep. 6:373712016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng C, Shan W, Huang W, Ding Z, Cui G,
Liu F, Lu W, Xu J, He W and Yin Z: ACY-1215 exhibits
anti-inflammatory and chondroprotective effects in human
osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB
signaling pathways. Biomed Pharmacother. 109:2464–2471. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing L, Zhang X, Feng H, Liu S, Li D,
Hasegawa T, Guo J and Li M: Silencing FOXO1 attenuates
dexamethasone-induced apoptosis in osteoblastic MC3T3-E1 cells.
Biochem Biophys Res Commun. 513:1019–1026. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li S, Jiang H and Gu X: Echinacoside
suppresses dexamethasone-induced growth inhibition and apoptosis in
osteoblastic MC3T3-E1 cells. Exp Ther Med. 16:643–648.
2018.PubMed/NCBI
|
|
21
|
Han D, Gu X, Gao J, Wang Z, Liu G, Barkema
HW and Han B: Chlorogenic acid promotes the Nrf2/HO-1
anti-oxidative pathway by activating p21 Waf1/Cip1 to resist
dexamethasone-induced apoptosis in osteoblastic cells. Free Radic
Biol Med. 137:1–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen HT, Liu H, Mao MJ, Tan Y, Mo XQ, Meng
XJ, Cao MT, Zhong CY, Liu Y, Shan H and Jiang GM: Crosstalk between
autophagy and epithelial-mesenchymal transition and its application
in cancer therapy. Mol Cancer. 18:1012019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Z, Liu S, Fu T, Peng Y and Zhang J:
Microtubule destabilization caused by silicate via HDAC6 activation
contributes to autophagic dysfunction in bone mesenchymal stem
cells. Stem Cell Res Ther. 10:3512019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Shi ZY, Feng J and Cao JK: HDAC6
regulates dental mesenchymal stem cells and osteoclast
differentiation. BMC Oral Health. 18:1902018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ota S, Zhou ZQ, Romero MP, Yang G and
Hurlin PJ: HDAC6 deficiency or inhibition blocks FGFR3 accumulation
and improves bone growth in a model of achondroplasia. Hum Mol
Genet. 25:4227–4243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Liu F, Huang W, Wang J, Wan YP, Li
M, Pang YQ and Yin ZS: Ricolinostat (ACY-1215) inhibits VEGF
expression via PI3K/AKT pathway and promotes apoptosis in
osteoarthritic osteoblasts. Biomed Pharmacother. 118:1093572019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Komori T: Regulation of skeletal
development by the Runx family transcription factors. J Cell
Biochem. 95:445–453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Plotkin L, Manolagas S and Bellido T:
Glucocorticoids induce osteocyte apoptosis by blocking focal
adhesion kinase-mediated survival. Evidence for inside-out
signaling leading to anoikis. J Biol Chem. 282:24120–24130. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rauch A, Seitz S, Baschant U, Schilling
AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A,
schmidt-ullrich R, et al: Glucocorticoids suppress bone formation
by attenuating osteoblast differentiation via the monomeric
glucocorticoid receptor. Cell Metab. 11:517–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim HJ, Zhao H, Kitaura H, Bhattacharyya
S, Brewer JA, Muglia LJ, Ross FP and Teitelbaum SL: Glucocorticoids
suppress bone formation via the osteoclast. J Clin Invest.
116:2152–2160. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li ZY, Li QZ, Chen L, Chen BD, Zhang C,
Wang X and Li WP: HPOB, an HDAC6 inhibitor, attenuates
corticosterone-induced injury in rat adrenal pheochromocytoma PC12
cells by inhibiting mitochondrial GR translocation and the
intrinsic apoptosis pathway. Neurochem Int. 99:239–251. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li RJ and Liu J: Pharmacogenetics advances
of glucocorticoid resistance and polymorphism of glucocorticoid
receptor. Chin J New Drugs. 24:1246–1254. 2015.
|
|
34
|
Vandevyver S, Dejager L and Libert C: On
the trail of the glucocorticoid receptor: Into the nucleus and
back. Traffic. 13:364–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X,
Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB and Yao TP: HDAC6
regulates Hsp90 acetylation and chaperone-dependent activation of
glucocorticoid receptor. Mol Cell. 18:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Espallergues J, Teegarden SL, Veerakumar
A, Boulden J, Challis C, Jochems J, Chan M, Petersen T, Deneris E,
Matthias P, et al: HDAC6 regulates glucocorticoid receptor
signaling in serotonin pathways with critical impact on stress
resilience. J Neurosci. 32:4400–4416. 2012. View Article : Google Scholar : PubMed/NCBI
|
